Autopsy report · NCT05928806

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

“Interim Analysis”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Suspended: paused, and may or may not restart.
• 120 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 2

Sponsor

Michael B. Atkins, MD

Sponsor type

University, hospital or other

Conditions

Advanced Renal Cell Carcinoma

Interventions

Botensilimab; Balstilimab; Ipilimumab; Nivolumab

Participants

120 (planned, not actual)

Sites

13

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.